SNSE Stock Overview
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sensei Biotherapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.04 |
52 Week High | US$1.93 |
52 Week Low | US$0.51 |
Beta | 0.091 |
1 Month Change | 37.75% |
3 Month Change | 49.47% |
1 Year Change | -21.21% |
3 Year Change | -91.54% |
5 Year Change | n/a |
Change since IPO | -94.50% |
Recent News & Updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Shareholder Returns
SNSE | US Biotechs | US Market | |
---|---|---|---|
7D | -2.8% | -0.5% | 0.6% |
1Y | -21.2% | 9.6% | 29.5% |
Return vs Industry: SNSE underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: SNSE underperformed the US Market which returned 29.8% over the past year.
Price Volatility
SNSE volatility | |
---|---|
SNSE Average Weekly Movement | 10.8% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNSE's share price has been volatile over the past 3 months.
Volatility Over Time: SNSE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 28 | John Celebi | https://www.senseibio.com |
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company’s pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.
Sensei Biotherapeutics, Inc. Fundamentals Summary
SNSE fundamental statistics | |
---|---|
Market cap | US$29.08m |
Earnings (TTM) | -US$34.10m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs SNSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SNSE income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$34.10m |
Earnings | -US$34.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.36 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did SNSE perform over the long term?
See historical performance and comparison